Optimizing a Unique Cancer Vaccine for Intradermal Delivery

September 15, 2017
Muctarr Sesay
Muctarr Sesay

Muctarr Sesay, PhD, is chief scientific officer and vice-president of Bioconjugation at Goodwin Biotechnology.

Mark Tomai

Steven Fuller

Steven Fuller, PhD, is chief operating officer at Panacea Pharmaceuticals.

John Price

John Price is the global marketing communications manager at 3M.

Dave Cunningham

Dave Cunningham is director, corporate development at Goodwin Biotechnology.

BioPharm International, BioPharm International-09-15-2017, Volume 2017 eBook, Issue 2
Pages: 31-35

Using a hollow microstructured transdermal system to deliver vaccine directly to the dermis.

3M Drug Delivery Systems and Panacea Pharmaceuticals are collaborating to deliver Panacea’s investigational cancer vaccine, PAN- 301-1, directly to the dermis via the 3M hollow microstructured transdermal system (hMTS).

PAN-301-1 vaccine is a biologic that cannot be administered orally, or via a transdermal patch; therefore, it was thought that intradermal delivery to the skin could potentially be the optimal route of administration. The hMTS offers high-volume, reproducible, direct delivery capability to the highly-vascularized dermis.

Download the



Article Details

BioPharm International eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 31-35


When referring to this article, please cite it as S. Fuller et al., "Optimizing a Unique Cancer Vaccine for Intradermal Delivery, " BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).